ZIOPHARM Oncology’s (ZIOP) “Hold” Rating Reiterated at Raymond James Financial

ZIOPHARM Oncology (NASDAQ:ZIOP)‘s stock had its “hold” rating restated by research analysts at Raymond James Financial in a research report issued to clients and investors on Monday.

Several other analysts have also recently issued reports on ZIOP. ValuEngine cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. BidaskClub cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Friday, November 10th. Finally, HC Wainwright restated a “buy” rating and issued a $9.50 target price on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $12.58.

ZIOPHARM Oncology (NASDAQ ZIOP) traded up $0.09 during midday trading on Monday, reaching $4.43. The company had a trading volume of 1,017,300 shares, compared to its average volume of 1,385,587. ZIOPHARM Oncology has a 1 year low of $3.90 and a 1 year high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) earnings per share. equities analysts predict that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.

In related news, CEO Laurence James Neil Cooper bought 6,440 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares in the company, valued at $5,071,861.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZIOP. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter worth $104,000. Amalgamated Bank grew its holdings in shares of ZIOPHARM Oncology by 12.9% during the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares during the period. Oppenheimer & Co. Inc. grew its holdings in shares of ZIOPHARM Oncology by 50.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 6,000 shares during the period. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology during the 2nd quarter worth $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter worth $141,000. Institutional investors and hedge funds own 40.25% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/ziopharm-oncologys-ziop-hold-rating-reiterated-at-raymond-james-financial.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply